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Abstract
Background: Feline leukemia virus (FeLV)-945, a member of the FeLV-A subgroup, was previously isolated from a
cohort of naturally infected cats. An unusual multicentric lymphoma of non-T-cell origin was observed in natural
and experimental infection with FeLV-945. Previous studies implicated the FeLV-945 surface glycoprotein (SU) as a
determinant of disease outcome by an as yet unknown mechanism. The present studies demonstrate that FeLV-
945 SU confers distinctive properties of binding to the cell surface receptor.
Results: Virions bearing the FeLV-945 Env protein were observed to bind the cell surface receptor with significantly
increased efficiency, as was soluble FeLV-945 SU protein, as compared to the corresponding virions or soluble
protein from a prototype FeLV-A isolate. SU proteins cloned from other cohort isolates exhibited increased binding
efficiency comparable to or greater than FeLV-945 SU. Mutational analysis implicated a domain containing variable
region B (VRB) to be the major determinant of increased receptor binding, and identified a single residue, valine
186, to be responsible for the effect.
Conclusions: The FeLV-945 SU protein binds its cell surface receptor, feTHTR1, with significantly greater efficiency
than does that of prototype FeLV-A (FeLV-A/61E) when present on the surface of virus particles or in soluble form,
demonstrating a 2-fold difference in the relative dissociation constant. The results implicate a single residue, valine
186, as the major determinant of increased binding affinity. Computational modeling suggests a molecular
mechanism by which residue 186 interacts with the receptor-binding domain through residue glutamine 110 to
effect increased binding affinity. Through its increased receptor binding affinity, FeLV-945 SU might function in
pathogenesis by increasing the rate of virus entry and spread in vivo, or by facilitating entry into a novel target cell
with a low receptor density.
Background
Feline leukemia virus (FeLV) is a naturally occurring
gammaretrovirus that infects domestic cats. The out-
come of FeLV infection is variable, including malignant,
proliferative and degenerative diseases of lymphoid,
myeloid and erythroid origin. Determinants of disease
outcome are not well understood, but likely involve
both viral and host factors. FeLV, like other natural ret-
roviruses, does not occur as a single genomic species
but as a closely related, genetically complex family.
Sequence variation among natural isolates occurs most
commonly in the viral long terminal repeat (LTR) and
in the surface-exposed envelope glycoprotein (SU) [1,2].
An unusual natural isolate, designated FeLV-945, was
previously identified as the predominant isolate in a
geographic and temporal cohort of naturally infected
cats [3,4]. The predominant disease presentation in the
cohort was a multicentric lymphoma of non-T-cell ori-
gin detected in twelve cases, one of which was the origi-
nal source of FeLV-945. The cohort also included four
cases of thymic lymphoma, one case of mast cell leuke-
mia, two cases of myeloproliferative disease and two
cases of anemia [3-5]. FeLV-945 has been classified as a
member of the FeLV-A subgroup, based on host range
and analysis of superinfection interference and on
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bers of FeLV-A are ecotropic in host range and utilize
feTHTR1, a thiamine transporter on the target cell sur-
face, as a receptor for entry [7].
FeLV-945 differs in sequence from a prototype mem-
ber of FeLV subgroup A, FeLV-A/61E, in the LTR and
in the SU gene [3,6,8,9]. Infection with 61E/945L, a
mutant in which the FeLV-945 LTR was substituted for
that of FeLV-A/61E, resulted in the relatively rapid
induction of thymic lymphoma of T-cell origin. Thus,
introduction of the FeLV-945 LTR induced the same
tumor as FeLV-A/61E, but did so more rapidly [9]. By
contrast, infection with 61E/945SL, a mutant in which
both the FeLV-945 LTR and SU gene were substituted
for those of FeLV-A/61E, resulted in the rapid induction
of multicentric lymphoma of B-cell origin, thus recapitu-
lating the predominant disease detected in the natural
cohort [9]. Taken together, these findings implicated the
FeLV-945 LTR as a determinant of the rate of disease
induction, and FeLV-945 SU as the determinant of dis-
ease spectrum. The mechanism by which FeLV-945 SU
might influence disease outcome is not known.
As the receptor-binding protein of the virus, natural
variation in SU is associated with significant functional
impact on receptor utilization, thereby influencing cell
tropism, rate of spread, and disease outcome [1,2,10-14].
The FeLV SU protein, analogous to the closely related
murine leukemia viruses, contains two amino-terminal
hypervariable regions, designated variable region A
( V R A )a n dv a r i a b l er e g i o nB( V R B ) ,t h a tc o m p r i s et h e
receptor binding domain [1]. Previous work has demon-
strated that the VRA domain is the primary determinant
of receptor interaction and is sufficient for receptor
binding, while the VRB domain is necessary for efficient
infection [15-21]. Secondary determinants for receptor
binding have also been identified in the carboxy-term-
inal region of SU and in a central proline-rich region
(PRR) known to mediate conformational changes
required for virus entry [17,22-24]. FeLV-945 SU differs
from that of FeLV-A/61E to a larger extent than other
known FeLV-A isolates differ among themselves [3].
Point mutations in FeLV-945 SU, relative to FeLV-A/
61E, are largely contained within protein domains hav-
ing roles in receptor recognition and entry [3,6].
In the present study, unique properties of FeLV-945
SU were characterized that may play a role in its ability
to direct disease outcome. Target cell receptor binding
was compared between the FeLV-945 and FeLV-A/61E
SU proteins. FeLV-945 SU was shown to exhibit an
increased efficiency of receptor binding as compared to
FeLV-A/61E using a variety of experimental conditions,
both when presented in virus particles and in soluble
form. The SU proteins of other isolates from the cohort
were also found to exhibit an increase in receptor
binding efficiency that was comparable to or greater
than that observed with FeLV-945 SU. Mutational ana-
lyses implicated a region containing the VRB domain of
FeLV-945 SU as the major determinant of the distinctive
receptor-binding phenotype, and identified a single
amino acid residue as primarily responsible for the
effect.
Results
Relative binding activity of virus particles bearing FeLV-
945 Env and of soluble SU proteins
Flow cytometric binding assays were first performed to
assess the relative strength of receptor binding by virus
particles bearing the Env protein of FeLV-945 or of pro-
totype FeLV-A/61E. For this purpose, equivalent infec-
tious titer of particles bearing either Env protein were
allowed to bind to feline 3201 T-lymphoid cells, after
which binding was detected using monoclonal antibody
C11D8 directed against FeLV SU. The results demon-
strated that virus particles bearing FeLV-945 SU bind to
the cell surface receptor significantly more efficiently
than do particles bearing the FeLV-A/61E SU (p <
0.001; Figure 1). While these studies suggest differential
binding properties of the viruses examined, the experi-
ment as performed cannot account for the possibility
that FeLV SU may be present in higher amounts, or
may be differentially displayed, on the surface of virus
particles in a manner as to influence receptor binding
affinity. To control for these possibilities, soluble FeLV-
945 and FeLV-A/61E SU proteins were expressed and
quantified precisely by western blot analysis using anti-
SU antibody C11D8 and an infrared dye-conjugated sec-
ondary antibody followed by densitometric analysis. The
presence of equivalent mass amounts of protein was
then verified visually using chemiluminescent western
blot analysis. Having quantified the proteins, equivalent
mass amounts were then used in flow cytometric bind-
ing assays on feline 3201 T-cells using C11D8 antibody.
By this analysis, FeLV-945 SU was observed to bind cell
surface receptor with greater efficiency than did FeLV-
A/61E SU (Figure 2A-B). Replicate binding assays, using
four independently prepared and quantified protein pre-
parations, demonstrated the increased binding of FeLV-
945 SU to be statistically significantly higher than that
of FeLV-A/61E SU (p < 0.001; Figure 2C). Enhanced
binding of FeLV-945 SU relative to FeLV-A/61E was
also observed on other feline cells lines including FEA
and AH927 cells (data not shown). Further, a statisti-
cally significant increase in cell surface receptor binding
was observed on MDTF/H2 [25], a mouse cell line engi-
neered to express the FeLV-A receptor (p < 0.001; Fig-
ure 2D). C11D8, the monoclonal antibody used to
detect SU binding in the assays described above, recog-
nizes an epitope conserved between FeLV-A/61E and
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Page 2 of 17FeLV-945 SU proteins [26]. To further confirm the
enhanced cell surface binding phenotype of FeLV-945
SU, binding assays were performed using an antibody
that recognizes the HA epitope tag fused to the C-ter-
minus of the soluble SU proteins. This measure also
demonstrated the binding of FeLV-945 SU to be statisti-
cally significantly greater than that of FeLV-A/61E SU
(p < 0.001; Figure 2E). To determine whether the
increased receptor binding of FeLV-945 SU could be
observed over a broad range of protein concentrations,
binding assays were performed using FeLV-A/61E or
FeLV-945 SU in equivalent mass amounts varying over
a 100-fold range. A statistically significant increase in
binding activity of FeLV-945 SU was observed at each
c o n c e n t r a t i o nt e s t e de x c e p ta tt h eh i g h e s ta m o u n t( F i g -
ure 3A - E). Nonlinear regression analysis of the results
using saturation binding equations revealed a 2-fold dif-
ference in dissociation constant (Kd; Figure 3F).
As described above, FeLV-945 is a representative iso-
late from a natural cohort of infected animals in which
the predominant disease presentation was a distinctive
multicentric lymphoma of non-T-cell origin [3-5]. In
previous studies, proviral DNA was amplified by PCR
from several cases of multicentric lymphoma (945, 922,
1046, 1049) and from a case of myeloproliferative dis-
ease (1306). Sequence analysis of the SU genes demon-
strated close relatedness but not identity to FeLV-945,
although host range and superinfection interference ana-
lysis demonstrated a phenotype consistent with FeLV
subgroup A [6]. Sequence comparison demonstrated a
set of residues in common among isolates from the
cohort that are distinct from previously characterized
SU proteins from subgroup A members FeLV-A/61E,
FeLV-A/3281 and FeLV-A/Glasgow. The latter are
nearly identical to each other despite having been iso-
lated from distant geographic locations over a period of
many years [27], but are clearly distinct from the cohort
isolates within the functional domains of SU (Figure
4A). To examine whether the observed commonalities
in SU sequence confer the increased receptor binding
activity typical of FeLV-945 on other isolates from simi-
lar disease outcome, pseudotype particles bearing Env
proteins from FeLV-945, FeLV-922, FeLV-1049, FeLV-
1306, and FeLV-1046A [6] were used for flow cyto-
metric binding assays on feline 3201 T-cells. The results
demonstrated cell surface receptor binding activity com-
parable to or significantly greater than that of pseudo-
type particles bearing FeLV-945 Env. Receptor binding
by FeLV-922 or FeLV-1046A Env pseudotypes was sig-
nificantly increased as compared to pseudotypes bearing
the other Env proteins examined (p < 0.001; Figure 4B).
Mutational analysis does not implicate the consensus VRA
domain of FeLV-945 SU as a determinant of binding
phenotype
To identify the domain(s) within FeLV-945 SU responsi-
ble for the increased binding affinity, we first considered
VRA since that domain has been previously identified as
the major determinant of receptor interaction in murine
and feline gammaretroviral SU proteins [15-21]. We
began by examining the predicted crystal structure of
FeLV-945 VRA to identify potential areas of interest as
compared to prototype FeLV-A. Crystal structure of the
receptor-binding domain of FeLV subgroup B SU has
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Figure 1 Comparative binding assays of virus particles bearing
the Env protein of FeLV-A/61E or of FeLV-945. A. Feline 3201
cells were incubated with equivalent numbers of virus particles
bearing the envelope protein of FeLV-A/61E (61E Env) or FeLV-945
(945 Env), followed by incubation with monoclonal antibody C11D8
to detect the surface-bound viral SU protein and then with an Alexa
Fluor 488-conjugated secondary antibody. Virus binding was
analyzed by flow cytometry. A representative histogram is shown,
demonstrating the binding activity of the particles as indicated and
a negative control in which no virus was included in the assay
(shaded). B. The geometric mean fluorescence of quadruplicate
samples from individual assays is indicated, as is the mean of
replicate experiments (horizontal bar). Asterisk indicates statistical
significance (*; p < 0.001).
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Figure 2 Comparative binding assays of soluble SU proteins of FeLV-A/61E or FeLV-945. A. A representative histogram is shown from a
comparative flow cytometric binding assay demonstrating the binding activity of FeLV-A/61E SU (61E; gray shaded) or FeLV-945 SU (945; black
shaded). Soluble SU proteins were quantified precisely using anti-SU antibody C11D8. Feline 3201 cells were incubated with equivalent mass
amounts of either SU protein for one hour, followed by incubation with C11D8 antibody to detect the surface-bound viral SU proteins and then
with an Alexa Fluor 488-conjugated secondary antibody. Negative controls (open histograms) included cell supernatants of transfections with the
empty expression vector, pCS2/Ctrl, and each SU with isotype control antibody. B. Chemiluminescent western blot analysis of equivalent mass
amounts of FeLV-A/61E and FeLV-945 SU proteins using C11D8 antibody as probe is shown to validate the precision of the infrared
quantification. Negative control was supernatants of cells transfected with pCS2/Ctrl. C-D . Geometric mean fluorescence of replicate binding
assays performed using four independently generated and quantified batches of FeLV-A/61E and FeLV-945 SU protein on either feline 3201 cells
(C) or murine MDTF/H2 cells (D) which express the FeLV-A receptor. Supernatant of mock- or pCS2/Ctrl-transfected cells were used as a negative
control. The mean of replicate experiments is represented (horizontal bar). Asterisk indicates statistical significance (*; p < 0.001). E. Flow
cytometric binding assays performed exactly as in (A) except that analysis was performed using an antibody to detect the HA tag at the C-
terminus of soluble SU proteins. Shown are a representative histogram (left), anti-HA chemiluminescent western blot analysis of equivalent mass
amounts of SU proteins to validate quantification (inset), and geometric mean fluorescence of replicate binding assays (right; p < 0.001).
Negative controls included either SU protein with isotype control antibody (open histograms).
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ture has yet been described for FeLV-A. Thus, homol-
ogy modeling of the receptor binding domain in the SU
proteins of FeLV-A/61E and FeLV-945 was performed
using the known FeLV-B SU structure [28] as a model-
ing template for the SwissModel Program [29-31] (Fig-
ure 5A). Computational models thereby generated
predict a prominent loop in the VRA domain of both
FeLV-A/61E and FeLV-945 SU that is distinct in struc-
ture from FeLV-B and is predicted to protrude on the
receptor-binding surface (Figure 5A). The predicted
structure is a cysteine-delimited loop of 31 residues that
appears similar in conformation in FeLV-945 and FeLV-
A/61E. However, the loop sequence includes five resi-
dues that diverge between FeLV-945 and FeLV-A/61E,
thereby implicating the divergent residues in the differ-
ing receptor binding phenotypes of the FeLV-945 and
FeLV-A/61E SU proteins (Figure 5B). To test the
hypothesis that the FeLV-945 sequence in the predicted
VRA domain loop confers increased binding efficiency,
site-directed mutagenesis was utilized to replace the five
divergent residues in the sequence of FeLV-A/61E SU
with those of FeLV-945, yielding a mutant SU gene
designated 61E/945-5. Soluble SU expressed by 61E/
945-5 was then prepared and quantified for use in com-
parative binding assays with SU proteins from FeLV-945
and FeLV-A/61E. The results demonstrated that the
binding phenotype of the 61E/945-5 mutant SU is statis-
tically indistinguishable from that of the FeLV-A/61E
parent protein (Figure 5C, left). Equivalent mass
Figure 3 Increased binding activity of FeLV-945 SU is observed over a 100-fold range of SU concentration. A. - E. FeLV-945 SU or FeLV-
A/61E SU proteins in equivalent mass amounts over a 100-fold range (0.1X - 10X) were incubated with feline 3201 cells and processed for flow
cytometric binding assays as described in Figure 2. Representative histograms are shown, demonstrating the binding activity of FeLV-A/61E SU
(gray shaded) or FeLV-945 SU (black shaded). Negative controls (open histograms) included supernatants from mock-transfected cells (solid line),
FeLV-A/61E SU with isotype control antibody (dotted line), and FeLV-945 SU with isotype control antibody (dashed line). Indicated at each SU
concentration is the result of statistical analysis of replicate binding assays using four independently generated and infrared-quantified batches of
SU proteins. A statistically significant increase in geometric mean fluorescence for FeLV-945 SU binding was considered p < 0.05. F. Relative
dissociation constants (Kd) were determined from the data shown in A - E by nonlinear regression analysis using saturation binding equations
with an assumption of one site-specific binding (GraphPad Prism5.0).
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as confirmed by quantitative western blot analysis (Fig-
u r e5 C ,r i g h t ) .T h er e c i p r o c a lm u t a n t ,9 4 5 / 6 1 E - 5 ,w a s
also constructed to replace the five divergent residues in
t h es e q u e n c eo fF e L V - 9 4 5S Uw i t ht h o s eo fF e L V - A /
61E. Soluble SU expressed by 945/61E-5 was precisely
quantified and used in comparative binding assays. The
results demonstrated the binding phenotype of the 945/
61E-5 mutant to be statistically indistinguishable from
that of FeLV-945 SU (data not shown).
Having determined that the divergent residues within
consensus VRA do not determine receptor-binding affi-
nity, a more comprehensive region surrounding VRA
was then examined through the use of substitution
mutants. Segments of the FeLV-A/61E SU gene were
replaced with corresponding segments of FeLV-945 SU
A. 
B. 
* 
* 
        *  
        1                                                 VRA                                  113 
A/61E:  ANPSPHQIYNVTWVITNVQTNTQANATSMLGTLTDVYPTLHVDLCDLVGDTWEPIVLSPTNVKHGARYPSSKYGCKTTDRKKQQQTYPFYVCPGHAPSLGPKGTHCGGAQDGF 
A/3281: -----------------------------------A-------------N-------D----------S-------------------------------------------- 
A/Glas: -----------------------------------A---------------------N----------S-------------------------------------------- 
945:    -----------------------------------A------------------L--D-N--R-----S----------------------------GM-------------- 
922:    ------------------------T----------A-------------N----L--D-N--R-----S----------------------------GM--------------  
1046:   ---G-P------R-----------------A----A------------------LA-D-K--RY----SD---------------------------GM-------------- 
1049:   -----------------------------------A------------------L--D-N--R-----S----------------I-----------GM-------------- 
1306:   -----------------------------------A----Y-------------L--D-N--R-----S--------------------------T-GM-------------- 
        114       **                    VRB                                                    **           PRR        226 
A/61E:  CAAWGCETTGEAWWKPSSSWDYITVKRGSSQDNNCEGKCNPLILQFTQKGKQASWDGPKMWGLRLYRTGYDPIALFTVSRQVSTITPPQAMGPNLVLPDQKPPSRQSQTGSKV 
A/3281: ---------------------------------S----------------R-------------------------------------------------------------- 
A/Glas: ----------------T----------------S--------V-------R-------------------------------------------------------------- 
945:    --------------N-T------------N---S-T------V-------R---------------------V------------------------------------E--- 
922:    --------------N-T----------------S--------V-------R---------------------V------------M-----------------------E--- 
1046:   --------------N-T----------------S--------V-------R---------------------V------------------------------------E--- 
1049:   --------------N-T----------------S-T------V-------R---------------------V------------------------------------E--- 
1306:   --------------N-T--------------V-S--------V-------R--------L------------V------------------------------------E--- 
        227                                                                                                           339 
A/61E:  ATQRPQTNESAPRSVAPTTVGPKRIGTGDRLINLVQGTYLALNATDPNKTKDCWLCLVSRPPYYEGIAILGNYSNQTNPPPSCLSIPQHKLTISEVSGQGLCIGTVPKTHQAL 
A/3281: ----L------S--------V----------------------------------------------------------------T--------------------------- 
A/Glas: -------------------M-----------------------------------------------------------------T--------------M------------ 
945:    --------T-T-G----A-MS----------------------------------------------------------------T---------------------R----- 
922:    --------T-T-G----A-MS------R---------------------------------------------------------T---------------------M--R-- 
1046:   --------T-T-G----A-MS-----------------------------------------------------SH-D-------T-P--------------M----M--R-- 
1049:   --------T-T-G--T-A-MS---V------------------------------------------------------------T---------------------R----- 
1306:   --------T-T-G----A-MS----------------------------------------------------------------T---------------------M--R-- 
        340               *                        412 
A/61E:  CNKTQQGHTGAHYLAAPNGTYWACNTGLTPCISMAVLNWTSDFCVLIELWPRVTYHQPEYVYTHFAKAVRFRR 
A/3281: --E---------------------------------------------------------------------- 
A/Glas: ------------------------------------------------------------------------- 
945:    -----------------------------------------------------------------D-T--L-- 
922:    -----------------------------------------------------------------D-T--L-- 
1046:   ------E---VR---------------------I--------- 
1049:   -----------------------------------------------------------------D-T--L--  
1306:   --E----------------------------------------------G- 
Figure 4 Pseudotype virus particles bearing the Env protein from other cohort isolates exhibit binding properties equivalent to, or
significantly greater than, FeLV-945. A. Sequence comparison of SU proteins from prototype FeLV-A isolates FeLV-A/61E [GenBank:AAA93093],
FeLV-A/3281 [GenBank:AAA43051] and FeLV-A/Glasgow [GenBank:AAA43053], from FeLV-945 [GenBank:AAT76450] and from other representatives
of the cohort. FeLV-922 [GenBank:AAT76452], FeLV-1046A [GenBank:AAT76457] and FeLV-1049 [GenBank:AAT76458] were isolated from
multicentric lymphomas. FeLV-1306 [GenBank:AAT76463] was isolated from myeloproliferative disease. Indicated is the complete amino acid
sequence of the mature SU protein encoded by each isolate. The sequence encoded by FeLV-A/61E is shown, identity to FeLV-A/61E is
indicated (-), as are amino acid substitutions by one-letter code. The positions of previously identified functional domains VRA, VRB and PRR are
underlined. Asterisks indicate positions of the regions used to create substitution mutants shown in Figure 6A and described in the text. B. Flow
cytometric binding assays were performed as in Figure 1 except using equivalent titers of pseudotyped viral particles bearing the envelope
proteins (Env) of FeLV-945, FeLV-922, FeLV-1049, FeLV-1306, or FeLV-1046A. The geometric mean fluorescence from individual assays is shown, as
is the mean of three independent replicate experiments (horizontal bars). Asterisk indicates statistical significance (*; p < 0.001).
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Figure 5 A loop structure predicted by computational modeling in the VRA domain of FeLV-A is not sufficient to confer the binding
phenotype of FeLV-945 SU. A. Ribbon diagram of homology models of the receptor binding domain in FeLV-A/61E and FeLV-945 SU proteins.
Homology modeling was performed using the SwissModel Program and the known crystal structure of the receptor binding domain of FeLV-B
SU (FeLV-B 1LCS) as a modeling template. A prominent loop (circled) was predicted by the models within the VRA domain of FeLV-A/61E and
FeLV-945 proteins, and is distinct from the structure of FeLV-B in the same region. B. Comparison of amino acids sequences of FeLV-A/61E and
FeLV-945 in the predicted VRA domain loop. The five amino acid differences between the sequences are indicated by shading. C. Comparative
flow cytometric binding assays of SU proteins encoded by FeLV-A/61E, FeLV-945 and 61E/945-5, a mutant in which the FeLV-945 sequence at all
of the five highlighted residues shown in Figure 5B was substituted by site-directed mutagenesis into FeLV-A/61E. Binding assays were
performed using feline 3201 cells as described in Figure 2. A representative histogram is shown (left panel), demonstrating the binding activity
of FeLV-A/61E SU (gray shaded), FeLV-945 SU (black shaded) and 61E/945-5 SU (open histogram, solid line). Negative controls (open histograms,
broken lines) include supernatants from pCS2/Ctrl-transfected cells and 61E/945-5 SU with isotype control antibody. Right panel shows
chemiluminescent western blot analysis to validate equivalent mass amounts of the SU proteins used in the binding assay as previously
quantified by infrared dye-based densitometry.
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either a VRA domain-containing region or both VRA-
and PRR-containing regions (61E/945-VRA or 61E/945-
VRA/PRR respectively, Figure 6A). Specifically, the sub-
stituted VRA-containing region included 124 residues
from alanine at position 1 to glutamic acid at position
124. The substituted PRR-containing region included
172 residues from glutamine at position 202 to methio-
nine at position 373 (Figure 4A). After substitution of
each region from FeLV-945 into FeLV-A/61E, soluble
SU proteins were then expressed from each mutant and
quantified precisely using infrared dye-based densito-
metric analysis of western blots. Equivalent mass
amounts of protein were used in comparative binding
assays as verified visually using chemiluminescent wes-
tern blot analysis. The resulting binding assays demon-
strated a phenotype for 61E/945-VRA and 61E/945-
VRA/PRR that was identical to the FeLV-A/61E parent
SU protein (Figure 6B). Thus, analysis of point muta-
tions and substitutions indicates that consensus VRA is
not a major determinant of FeLV-945 binding
phenotype.
Substitutional analysis implicates a VRB-containing region
as the major determinant of the binding phenotype
A region of SU containing the VRB domain was next
examined for contribution to the FeLV-945 binding phe-
notype. First, a substitution mutant was constructed in
which both VRA- and VRB-containing regions of FeLV-
A/61E were substituted with those of FeLV-945 (61E/
945-VRA/VRB; Figure 6A). The substituted VRB-con-
taining region included 77 residues from alanine at posi-
tion 125 to proline at position 201 (Figure 4A).
Comparative binding assays using equivalent mass
amounts of protein demonstrated the binding phenotype
of 61E/945-VRA/VRB SU to be nearly identical to
FeLV-945 SU (Figure 6C), thus implicating the VRB
domain. The reciprocal mutant 945/61E-VRA/VRB was
then constructed, in which FeLV-A/61E VRA and VRB
regions were substituted for those of FeLV-945. Consis-
tent with the implication of VRB as the relevant deter-
minant, comparative binding assays demonstrated a
phenotype of the 945/61E-VRA/VRB mutant that was
similar to FeLV-A/61E SU and significantly decreased
when compared to FeLV-945 SU (p < 0.01; Figure 6D).
Studies were next performed to delineate whether the
VRB domain-containing region alone was sufficient to
determine the binding phenotype. A mutant was con-
structed in which the VRB-containing region of FeLV-
945 alone was substituted into FeLV-A/61E SU to con-
struct a mutant designated 61E/945-VRB. Comparative
binding assays using equivalent mass amounts of protein
demonstrated the binding phenotype of 61E/945-VRB
SU to be similar to FeLV-945 SU although the increased
binding relative to FeLV-A/61E did not reach statistical
significance (Figure 7A). A reciprocal mutant was con-
structed, designated 945/61E-VRB, in which the VRB-
containing region of FeLV-A/61E was substituted into
that of FeLV-945. Comparative binding assays using
equivalent mass amounts of protein demonstrated a
binding phenotype for 945/61E-VRB SU that was statis-
tically indistinguishable from that of FeLV-A/61E SU
and significantly different from FeLV-945 SU (p < 0.001;
Figure 7B). These results implicate the 77-amino acid
VRB-containing segment as largely responsible for the
increased binding efficiency of FeLV-945 SU. The VRB-
containing segment exchanged in these studies includes
eight amino acid sequence differences between FeLV-
945 and FeLV-A/61E, three of which (positions 143,
147, and 149) are localized within consensus VRB (Fig-
ure 7C). Two of the differences, at positions 143 and
149, are not shared with other cohort isolates including
FeLV-922 and FeLV-1046, whose SU proteins exhibit
even more efficient receptor binding than FeLV-945.
The asparagine-to-serine change at position 147 is
shared among other cohort isolates as are the changes
at positions 128, 130, 156, 164 and 186.
Mutational analysis implicates a single residue as the
major determinant of binding phenotype
To identify the residues within the VRB-containing seg-
ment responsible for its influence on binding phenotype,
a point mutant was first constructed in which the aspar-
agine at residue 147 of FeLV-A/61E was replaced with
serine as appears in FeLV-945 (N147S). Comparative
binding assays using equivalent mass amounts of SU
proteins demonstrated the binding phenotype of N147S
SU to be indistinguishable from FeLV-A/61E (Table 1).
A point mutant was then constructed in which the resi-
dues at positions 143, 147 and 149 in FeLV-A/61E SU
were changed to those of FeLV-945 (VRB3aa). Com-
parative binding assays using equivalent mass amounts
of SU proteins demonstrated the binding phenotype of
VRB3aa SU to be indistinguishable from FeLV-A/61E
(Table 1). Thus, having identified no residues within
consensus VRB as responsible for the binding pheno-
type, mutational analysis was then performed at posi-
tions 128, 130,156,164 and 186 where additional
sequence differences were identified. Point mutants
were constructed in FeLV-A/61E in which the residues
at positions 128 and 130 or 156 and 164 were substi-
tuted with those of FeLV-945 (K128N/S130T and
I156V/K164R, respectively). Comparative binding assays
using equivalent mass amounts of SU proteins demon-
strated the binding phenotypes of K128N/S130T and
I156V/K164R to be indistinguishable from FeLV-A/61E
(Table 1). Only when the isoleucine-to-valine change at
position 186 was incorporated into the mutants was the
Bolin et al. Retrovirology 2011, 8:35
http://www.retrovirology.com/content/8/1/35
Page 8 of 17100 101 102 103 104
Alexa 488
61E/945-VRA/VRB 
B. 
61E/945-VRA  61E/945-VRA/PRR 
C. 
A. 
945/61E-VRA/VRB 
D. 
* 
1
10
100
1000
Control 61E  945  61E/945-VRA/VRB 
G
e
o
m
e
t
r
i
c
 
M
e
a
n
 
F
l
u
o
r
e
s
c
e
n
c
e
 
*  * 
1
10
100
1000
Control 61E  945  945/61E-VRA/VRB 
G
e
o
m
e
t
r
i
c
 
M
e
a
n
 
F
l
u
o
r
e
s
c
e
n
c
e
 
61E  E
61E  1E
61E  E 
61E  1E 
945  945 
945 
945 
mutant  ant  mutant  ant 
mutant  ant 
mutant 
1E
ant 
VRA PRR 
1 500 aa 
61E/945-VRA 
61E/945-VRA/VRB 
61E/945-VRA/PRR 
VRB 
412 aa  SU Protein 
Figure 6 Substitution of both FeLV-945 VRA and VRB is sufficient to confer the enhanced binding phenotype to FeLV-A/61E SU. A.
Diagram of the 412-amino acid FeLV-A/61E SU protein and mutants into which FeLV-945 sequences were substituted. Positions of the VRA, VRB,
and PRR domains are indicated (shaded boxes). FeLV-945 sequences that have been substituted into FeLV-A/61E SU to construct each mutant
are indicated (black boxes), and vertical lines represent the relative locations of amino acid sequence differences between the two SU proteins.
B. - D. Comparative flow cytometric binding assays of SU proteins encoded by FeLV-A/61E, FeLV-945 and substitution mutant SU proteins as
indicated. Binding assays were performed using feline 3201 cells as described in Figure 2. Representative histograms are shown, demonstrating
the binding activity of FeLV-A/61E SU (green), FeLV-945 SU (pink) and the substitution mutant indicated in each case (blue). Negative controls
included supernatants from pCS2/Ctrl-transfected or mock-transfected cells (gray) and each mutant SU with isotype control antibody (gold). Inset
in each panel shows chemiluminescent western blot analysis to validate equivalent mass amounts of the SU proteins used in the binding assay
as previously quantified by infrared dye-based densitometry. C. and D., Right panels. Replicate binding assays were performed using four (61E/
945-VRA/VRB) or two (945/61E-VRA/VRB) independently generated and infrared-quantified batches of SU proteins. The geometric mean
fluorescence from individual assays is shown, as is the mean of four independent replicate experiments (horizontal bar). Asterisk indicates
statistical significance (*; C: p < 0.05; D: p < 0.01).
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Page 9 of 17binding phenotype affected. Specifically, the K128N/
S130T and I156V/K164R mutants were furthered altered
to include the isoleucine-to-valine change at position
186 (K128N/S130T/I186V and I156V/K164R/I186V,
respectively). Comparative binding assays using equiva-
lent mass amounts of SU proteins demonstrated that
K128N/S130T/I186V and I156V/K164R/I186V SU
bound to receptor with increased efficiency and exhib-
ited a binding phenotype indistinguishable from 61E/
945-VRB (Table 1). Indeed, a point mutant of FeLV-A/
61E SU altered to contain only the isoleucine-to-valine
change at residue 186 demonstrated a binding pheno-
type statistically distinct from FeLV-A/61E SU and
equivalent to 61E/945-VRB SU (Figure 8A). A reciprocal
mutant, V186I, was constructed in which the isoleucine
characteristic of FeLV-A/61E at position 186 was substi-
tuted into FeLV-945 SU. Comparative binding assays
using equivalent amounts of SU proteins demonstrated
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Figure 7 FeLV-945 VRB is sufficient to confer the enhanced binding phenotype to FeLV-A/61E SU. A-B . Comparative flow cytometric
binding assays of SU proteins encoded by FeLV-A/61E, FeLV-945 and 61E/945-VRB (in A., left) or the reciprocal mutant, 945/61E-VRB (in B., left).
Binding assays were performed using feline 3201 cells as described in Figure 2. Representative histograms are shown, demonstrating the binding
activity of FeLV-A/61E SU (green), FeLV-945 SU (pink) and the substitution mutant indicated in each case (blue). Negative controls included
supernatants from pCS2/Ctrl-transfected cells (gray) and each mutant SU with isotype control antibody (gold). Inset in each panel shows
chemiluminescent western blot analysis to validate equivalent mass amounts of the SU proteins used in the binding assay as previously
quantified by infrared dye-based densitometry. Replicate binding assays were performed (right panels) using two (945/61E-VRB), three (61E/945-
VRB) or five (FeLV-A/61E and FeLV-945) independently generated and titered batches of SU proteins. The geometric mean fluorescence from
individual assays is shown, as is the mean of five independent replicate experiments (horizontal bar). Asterisk indicates statistical significance (*;
A: p < 0.01; B: p < 0.001). C. Amino acid sequence of the VRB-containing domain of FeLV/A-61E, compared to that of FeLV-945 and other cohort
isolates (FeLV-922, FeLV-1046A, FeLV-1306). Indicated by brackets is consensus VRB, and sequence differences are indicated by the amino acid
position number within the mature SU protein.
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Page 10 of 17a binding phenotype for V186I that was statistically sig-
nificantly reduced as compared to I186V and indistin-
guishable from FeLV-A/61E (Figure 8B). To confirm,
the binding assays were then repeated using an antibody
that recognizes the HA epitope tag fused to the C-ter-
minus of the soluble SU proteins. The results confirmed
the key finding that the I186V binding phenotype is sta-
tistically indistinguishable from that of 61E/945-VRB
a n dd i s t i n c tf r o mF e L V - A / 6 1 E( F i g u r e8 C ) .R e g a r d i n g
the reciprocal mutant, V186I, analysis with anti-HA
antibody demonstrated reduced binding as compared to
I186V but which did not reach the level of statistical
significance (Figure 8C). Taken together, these findings
do not implicate the consensus VRB domain as the
determinant of increased binding affinity, but rather
implicate a single residue at position 186 as the major
determinant of binding phenotype.
Computational modeling predicts a mechanism by which
residue 186 influences the increased binding affinity of
FeLV-945 SU
Computational modeling of the putative SU receptor-
binding surface demonstrates a change in structure
associated with the isoleucine-to-valine change at posi-
tion 186, and reveals a mechanism that may account for
the influence of that change on the binding affinity of
FeLV-945 SU (Figure 9). Specifically, modeling predicts
that the isoleucine-to-valine change at position 186
affects receptor binding by inducing a major change in
the position of an adjacent glutamine residue, Q110,
which is conserved in both SU proteins. In FeLV-A/61E
SU (Figure 9A), the relatively bulky isoleucine side chain
at position 186 effectively pushes Q110 into the lower
end of a large binding cleft, thus narrowing the lower
end. In FeLV-945 SU (Figure 9B), by comparison, the
more compact valine side chain at position 186 is
predicted to re-orient Q110 out of the putative binding
site at a roughly 90° angle from its position in FeLV-A/
61E SU (Figure 9C). The result is that Q110 does not
protrude into the lower end of the binding cleft, the
predicted consequence of which is that the lower end is
twice as wide when valine as compared to isoleucine
appears at position 186. The wider receptor-binding site
may represent a better surface conformation for interac-
tion of FeLV-945 SU with the receptor residues.
Discussion
FeLV-945 was isolated from a natural cohort of infected
cats in which the predominant disease presentation was
a distinctive multicentric lymphoma of non-T-cell origin
[3-5]. FeLV-945 was assigned through studies of host
range and superinfection interference to FeLV subgroup
A [6], although the FeLV-945 LTR and SU gene were
shown to contain unique sequence elements [3,6,8].
Indeed, when substituted into FeLV-A prototype isolate,
FeLV-A/61E, the unique LTR and SU gene of FeLV-945
were shown to redirect the outcome of infection from
T-cell lymphoma of the thymus occurring after pro-
longed latency to a relatively rapid induction of multi-
centric lymphoma of B-cell origin, thus recapitulating
the natural disease outcome seen with FeLV-945.
Further studies demonstrated that FeLV-945 SU is
strictly required for the shift in pathogenesis [9]. The
mechanism by which FeLV-945 SU acts to determine
the outcome of disease induction is not known. In the
present study, FeLV-945 SU was observed to bind feline
cells, or murine cells expressing the FeLV-A receptor,
with significantly increased efficiency as compared to
FeLV-A/61E SU, when present either in virus particles
(Figure 1) or in soluble form (Figure 2). These findings
were documented by flow cytometric binding assay
using a monoclonal antibody, C11D8, that recognizes an
Table 1 Summary of comparative flow cytometric binding assays performed using soluble SU proteins of FeLV-A/61E,
61E/945-VRB or mutant FeLV-A/61E SU proteins substituted of specific amino acids within and surrounding the
consensus VRB domain of FeLV-945
Soluble SU Protein
a Average GMF of Replicate Binding Assays
b Comparable Binding Phenotype
FeLV-A/61E 12.49 N/A
61E/945-VRB 22.67 N/A
VRB3aa 8.64 FeLV-A/61E
N147S 12.16 FeLV-A/61E
K128N/S130T 11.92 FeLV-A/61E
I156V/K164R 10.09 FeLV-A/61E
K128N/S130T/I186V 22.65 61E/945-VRB
I156V/K164R/I186V 21.69 61E/945-VRB
aComparative flow cytometric binding assays were performed using FeLV-A/61E, 61E/945-VRB, or mutated SU proteins named according to the individual FeLV-
945 amino acid residues substituted into FeLV-A/61E as shown in Figure 7C. Binding assays were performed using equivalent mass amounts of each SU protein
and feline 3201 cells.
bThe average geometric mean fluorescence (GMF) is shown for three (N147S), four (VRB3aa, I156V/K164R, K128N/S130T, I156V/K164R/I186V), or five (K128N/
S130T/I186V) replicate binding assays using three or four independently generated and titered batches of SU proteins.
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Figure 8 A single amino acid residue at position 186 accounts for the ability of a VRB-containing domain to confer increased receptor
binding affinity to FeLV-A/61E SU. A. A representative histogram from a comparative flow cytometric binding assay of SU proteins encoded
by FeLV-A/61E (green), 61E/945-VRB (orange) and I186V (blue) is shown (left). Binding assays were performed as described in Figure 2 using anti-
SU antibody C11D8. Negative controls include supernatants from pCS2/Ctrl-transfected cells (gray) and I186V SU with isotype control antibody
(gold). Inset shows chemiluminescent western blot analysis with C11D8 antibody to validate equivalent mass amounts of the SU proteins used
in the binding assay. Replicate binding assays were performed (right) using six (I186V) or four (FeLV-A/61E and 61E/945-VRB) independently
generated and titered batches of SU proteins (p < 0.05). B. A representative histogram (left) and geometric mean fluorescence of replicate flow
cytometric binding assays (right) is shown demonstrating the binding activity of SU proteins encoded by FeLV-A/61E (green), I186V (blue) or the
reciprocal mutant V186I (red). Negative controls included supernatants from pCS2/Ctrl-transfected cells (gray) and V186I SU with isotype control
antibody (gold). Replicate binding assays were performed as in A using four independently generated and titered batches of each SU protein (p
< 0.05). Inset shows chemiluminescent western blot analysis with C11D8 antibody to validate equivalent mass amounts of the SU proteins used
in the binding assay. C. Geometric mean fluorescence of replicate binding assays using soluble SU proteins expressed from FeLV-A/61E, 61E/945-
VRB, I186V, and V186I is shown (p < 0.05). Negative control is supernatant of pCS2/Ctrl-transfected cells. Comparative flow cytometric binding
assays were performed as in A except using anti-HA antibody to detect SU protein. Assays were performed with three (61E/945-VRB) or four
(FeLV-A/61E, I186V, V186I) independently generated and titered batches of SU proteins.
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SU proteins [26]. Thus, the enhanced receptor binding
phenotype of FeLV-945 SU is not likely to represent dif-
ferential binding of the C11D8 antibody. Confirmatory
results were obtained using an antibody that recognizes
the HA epitope tag fused to the C-terminus of the solu-
ble SU proteins (Figure 2 and 8).
Significantly increased efficiency of receptor binding
by soluble FeLV-945 SU was observed using different
feline cell lines, including 3201 T-lymphoid cells,
AH927 and FEA fibroblast lines (Figure 2 and data not
shown). Increased binding was observed over a 100-fold
range of SU concentration, with a statistically significant
difference observed at all but the highest concentration
(Figure 3A - E). These findings indicate that FeLV-945
SU binds receptor with greater affinity, and predicts that
FeLV-945 SU would bind the cell surface receptor more
efficiently under physiological conditions where the
amount of receptor and/or virus may be limiting. By vir-
tue of this phenotype, FeLV-945 SU might then act as a
determinant of pathogenesis by increasing the rate of
virus entry and spread in vivo, or by facilitating entry
into a novel target cell with a low receptor density. The
analysis further demonstrated a 2-fold difference in dis-
sociation constant (Kd;F i g u r e3 F ) ,w h i c h ,w h i l es e e -
mingly modest, might have a major impact during an
exponentially spreading infection in vivo. While we do
not yet know the functional impact of increased binding
affinity of FeLV-945 SU, it is useful to consider the
quantitative modeling of replicative advantage that may
be conferred by a mutation in the virus genome. Others
have calculated that a newly arising virus mutation
which affords a 1% replicative advantage would repre-
sent 50% of the virus population within 400 replication
cycles [32]. These observations indicate that a replicative
advantage (or in this case, increased affinity for recep-
tor-binding) need not be large to impact an exponen-
tially spreading infection.
T h ec o h o r tf r o mw h i c hF e L V - 9 4 5w a si s o l a t e dw a s
collected from a single veterinary practice in Pasadena,
California over a period of six years [3,4]. Considering
the limited geographic and temporal spread of the
cohort, the animals were presumably infected by a simi-
lar spectrum of natural FeLV isolates circulating among
the population. This possibility is supported by the
observation that SU genes isolated from other disease
cases in the cohort were found to share most of the
unique sequence features of FeLV-945 SU, and to exhi-
bit greater sequence identity to each other than to other
members of FeLV subgroup A across the functional
domains of SU (Figure 4A). This observation is particu-
larly remarkable since other previously described mem-
bers of FeLV subgroup A demonstrate near identity
across SU despite having been isolated from across the
world over a period of many years [1,2,27]. Pseudotype
virus particles bearing Env protein from cohort isolates
were shown to exhibit a receptor-binding phenotype
c o m p a r a b l et ot h a to fF e L V - 9 4 5S U ,o ri nt h ec a s eo f
922 and 1046A pseudotypes, significantly more efficient
binding (Figure 4B). These results support the hypoth-
esis that distinctive SU sequences across the functional
domains confer the increased binding efficiency charac-
teristic of FeLV-945 SU and other cohort isolates. To



61E  945 
Q110 
61E 
945 
Figure 9 Structural modeling predicts that residue 186 lies
near the end of the putative receptor binding cleft and
influences packing of the conserved residue glutamine 110
(Q110). A. - B. The receptor binding domains of FeLV-A/61E (A)
and FeLV-945 (B) were modeled using SwissModel and the
molecular surfaces were calculated and drawn using 3D Molecule
Viewer (Vector NTI, Invitrogen). Full views of the predicted surfaces
are shown in white and a close up of the putative binding cleft
(inset) is shown in cyan with residue 186 shown in green and
residue 110 shown in magenta. C. Spacefilled depictions of residue
186 (green) and residue 110 (magenta) show the predicted
difference in the position of Q110 between the SU of FeLV-A/61E
and FeLV-945.
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tional domains confers the binding phenotype, computa-
tional modeling was first performed to examine the
potential functional impact of amino acid differences in
the receptor-binding domain of FeLV-945 as compared
to FeLV-A/61E. While the crystal structure of the recep-
tor-binding domain of FeLV subgroup A is not available,
such structure is available for FeLV subgroup B [28].
Using the FeLV-B structure as a modeling template, a
cysteine-delimited loop of 31 amino acids was predicted
to occur in both FeLV-945 and FeLV-A/61E SU at a
position likely to involve the receptor-binding surface
(Figure 5A - B). This loop, contained fully within the
VRA domain, harbors five amino acid differences
between the two sequences (Figure 5B). The possible
impact of these changes was of interest, considering the
several demonstrations of VRA as the primary determi-
nant of receptor interaction in murine and feline gam-
maretroviral SU proteins [15-21]. Reciprocal substitution
of all five residues between the SU proteins of FeLV-945
and FeLV-A/61E, however, failed to influence the bind-
ing phenotype (Figure 5C). These findings indicate that
the sequence of the predicted VRA loop is not sufficient
to determine the binding phenotype.
To further delineate the responsible domain, substitu-
tion mutants were created in which regions containing
the VRA, PRR, and VRB domains of FeLV-945 SU and
FeLV-A/61E SU were reciprocally replaced (Figure 6A).
Comparative binding assays using equivalent mass
amounts of soluble SU protein confirmed that substitu-
tion of VRA, or VRA and PRR, did not influence the
binding phenotype of mutant SU proteins (Figure 6B).
By contrast, the reciprocal substitution of VRA and VRB
(Figure 6C - D), or of VRB alone (Figure 7A - B) gener-
ated mutant SU proteins whose binding phenotype reca-
pitulated the parent SU of the introduced domain.
Taken together, the comparative binding assays impli-
cate the VRB-containing substitution as the major deter-
minant of binding phenotype, but also indicate a
contribution of the VRA domain. Specifically, the substi-
tution of both VRA and VRB from FeLV-945 into FeLV-
A/61E was shown to recapitulate the FeLV-945 binding
phenotype (Figure 6C) but the substitution of VRB
alone does not (Figure 7A), thus suggesting a role for
VRA in conferring the full activity. The effect of VRA
on determining binding phenotype is apparently depen-
dent on interaction with VRB, since substitution of
FeLV-945 VRA into FeLV-A/61E did not affect binding
in the absence of FeLV-945 VRB (Figure 6B). The 124-
amino acid VRA-containing substitution constructed for
these studies includes eight amino acid sequence differ-
ences between FeLV-945 and FeLV-A/61E, seven of
which are localized within the consensus VRA domain
(positions 55, 58, 60, 63, 69, 98, 99; Figure 4A). All of
these substitutions are shared among cohort isolates, and
five of them represent the residues identified by compu-
tational modeling as potential contributors to binding
phenotype (Figure 5). However, substitution of the FeLV-
945 sequence into FeLV-A/61E at all five positions failed
to recapitulate the FeLV-945 binding phenotype, consis-
tent with the observation that replacement of the entire
VRA domain from FeLV-945 into FeLV-A/61E did not
influence binding in the absence of VRB substitution.
These results indicate that FeLV-945 VRB can positively
impact SU binding in the context of VRA from either
FeLV-A/61E or FeLV-945, but the optimal binding inter-
action is achieved in the presence of FeLV-945 VRA.
Within the VRB-containing segment implicated as the
major determinant of binding phenotype are eight
amino acid sequence differences between FeLV-945 and
FeLV-A/61E, three of which (positions 143, 147, and
149) are localized within consensus VRB. Mutational
analysis, however, demonstrated that these residues
could not confer the enhanced binding phenotype of
FeLV-945 VRB. Mutational analysis of four other resi-
dues (positions 128, 130, 156, 164) that neighbor con-
sensus VRB and are shared among other cohort isolates
similarly demonstrated that these do not influence rela-
tive binding affinity. Indeed, only when the isoleucine-
to-valine change at position 186 was incorporated into
the mutants was the binding phenotype affected (Table
1), and point mutation implicated the single valine resi-
due at position 186 in FeLV-945 SU as the major deter-
minant of increased binding affinity (Figure 8).
Computational modeling sheds light on the mechanism
by which valine 186 as represented in FeLV-945 may
influence increased binding affinity as compared to iso-
leucine 186 as represented in FeLV-A/61E (Figure 9).
Acting through an effect on position of the neighboring
residue Q110, the relatively bulky isoleucine side chain
at position 186 results in a narrowing of the predicted
receptor-binding cleft at its lower end (Figure 9A). By
contrast, the relatively compact valine side chain at posi-
tion 186 allows Q110 to assume an orientation out of
the receptor-binding cleft thus widening the lower end
approximately two-fold (Figure 9B). The impact on con-
formation of the receptor-binding cleft is then predicted
to influence the relative binding affinity for FeLV-A
receptor. This influence of valine 186 is apparently
further influenced by residues in VRA that make contact
with receptor, since a more optimal binding phenotype
is observed in the presence of VRA from FeLV-945 as
compared to that of FeLV-A/61E. This may explain why
FeLV-922 and FeLV-1046 SU proteins showed an even
greater binding affinity than FeLV-945, since both con-
tain valine 186 and additional sequence differences
within VRA that are not shared between the two or
with other cohort isolates (Figure 4). This hypothesis
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studies have shown the VRA domain to be sufficient for
infection, efficient infection is known to require the
VRB domain as well [15-21]. The present findings impli-
cate a single residue in the influence of VRB on FeLV-
945 SU binding affinity, and suggest a mechanism by
which that residue interacts with the VRA domain to
effect its influence.
Conclusions
The SU protein of FeLV-945, a unique natural isolate of
feline leukemia virus, directs the induction of non-T-cell
multicentric lymphoma through an as yet unknown
mechanism. FeLV-945 SU is shown here to bind its cell
surface receptor, feTHTR1, with significantly greater
efficiency than does prototype FeLV-A SU when present
on the surface of virus particles or in soluble form. The
increased binding activity demonstrates a 2-fold differ-
ence in Kd relative to prototype FeLV-A SU. Computa-
tional modeling and mutational analyses implicate a
region containing the VRB domain of FeLV-945 SU as
the major determinant of increased binding affinity,
although a region containing the VRA domain appears
to play a role. The results implicate a single residue
adjacent to consensus VRB, valine 186, as the major
determinant of increased binding affinity. Computational
modeling suggests a molecular mechanism by which
residue 186 interacts with residue Q110 to effect
increased binding affinity.
Methods
Cells and viruses
Feline 3201 cells, an FeLV-negative T-lymphoid line
derived from a natural thymic lymphoma, were main-
tained in a medium of 50% Leibovitz L-15 and 50%
RPMI 1640 with 15% fetal bovine serum (FBS). FEA
cells, a continuous line of feline embryonic fibroblasts,
were maintained in Eagle’s minimum essential medium
with 10% FBS and nonessential amino acids. AH927, a
continuous line of feline embryonic fibroblasts, was
maintained in Dulbecco’s Modified Eagle Medium
(DMEM) with 10% FBS. Murine MDTF/H2 cells, a gift
of Dr. Julie Overbaugh, represent a continuous line of
Mus dunni tail fibroblasts engineered to express the
FeLV-A receptor, feTHTR1, and were maintained in
DMEM with 10% FBS and 0.6 mg/ml geneticin [25].
Human embryonic kidney 293T/17 cells (ATCC CRL-
11268) were maintained in DMEM with 10% FBS. Mole-
cularly cloned, infectious proviral DNAs used in the
study include FeLV-A/61E [27] and the infectious
recombinant viruses 61E/945L and 61E/945SL. As
described previously, 61E/945L was generated by repla-
cement of the FeLV-A/61E LTR with that of FeLV-945
and 61E/945SL was generated by replacement of the
FeLV-A/61E LTR and SU gene with corresponding
sequences from FeLV-945 [6,8]. Pseudoptyped virus par-
ticles bearing envelope proteins of FeLV-945, FeLV-922,
FeLV-1049, FeLV-1306, or FeLV-1046 were constructed
as previously described [6].
SU expression constructs
CS2-FeLV-A-61E-SU-HA [13], a gift of Dr. Julie Over-
baugh, encodes the FeLV-A/61E SU gene corresponding
to amino acids 1 to 435, fused at the carboxy terminus
to a hemagglutinin (HA) epitope tag. CS2-FeLV-945-
SU-HA was generated by replacing a MscI to NcoI frag-
ment (basepair 100 to 1214) of the SU gene in CS2-
FeLV-61E-SU-HA with the corresponding fragment
from FeLV-945 [GenBank:AY662447]. An empty vector
control, designated pCS2/Ctrl, was generated by religa-
tion of BamHI-digested CS2-FeLV-A-61E-SU-HA. 61E/
945-VRA and 61E/945-VRA/VRB were generated by
replacing a HindIII-to-HindIII fragment or an NdeI-to-
Bsu36I fragment of CS2-FeLV-A-61E-SU-HA, respec-
tively, with the corresponding fragment of CS2-FeLV-
945-SU-HA. 61E/945-VRA/PRR was generated by repla-
cing a Bsu36I-to-NcoI fragment of 61E/945-VRA with
the corresponding fragment of CS2-FeLV-945-SU-HA.
945/61E-VRA/VRB was generated by replacing a NdeI-
to-Bsu36I fragment of CS2-FeLV-945-SU-HA with the
corresponding fragment of CS2-FeLV-61E-SU-HA. 61E/
945-VRB was generated by replacing a HindIII-to-Hin-
dIII fragment of 61E/945-VRA/VRB with the corre-
sponding fragment of CS2-FeLV-61E-SU-HA. A
reciprocal mutant, 945/61E-VRB, was made by replacing
a HindIII-to-HindIII fragment of 945/61E-VRA/VRB
with the corresponding fragment of CS2-FeLV-945-SU-
HA. SU genes bearing point mutations were generated
by site-directed mutagenesis (Stratagene, Agilent Tech-
nologies, Santa Clara, CA) using CS2-FeLV-61E-SU-HA
as template and using the indicated primers where the
introduced mutation in each case is underlined: 1) the
mutant designated 61E/945-5 using primer 5’-
ACTAGTGTTGGATCCTAACAACGTTCGGCATG-
GAGCTAGGTATAGCAGTAGCAAATATGGATG-
TAAAACTACAGATAG-3’, 2) the mutant designated
VRB3aa using primer 5’-GAGGGAGTAATCAGGA-
CAATAGCTGCACAGGAAAATGCAACCCCC-3’,3 )
the mutant designated N147S using primer 5’-GGGAG-
TAGTCAGGACAATAGCTGTGAGGG-3’,4 )t h e
mutant designated K128N/S130T using primer 5’-
GCAACCCCCTAGTCTTACAGTTCACCCAGAAGG-
GAAGACAAGCCTCTTGG-3’, 5) the mutant desig-
nated I156V/K164R using primer 5’-GGAGAAG-
CTTGGTGGAATCCCACCTCCTCATGG-3’,a n d6 )
the mutant designated I186V using primer 5’-
GGATATGACCCTGTCGCTTTATTCACGGTGTCCC-
GGCAGG-3’. The mutant designated V186I was
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using primer 5’-GGATATGACCCTATCGCCTTATT-
CACGGTATCCCGGCAGG-3’. The mutants designated
K128N/S130T/I186V and I156V/K164R/I186V were
generated using primer 5’-GGATATGACCCTGTCGC-
TTTATTCACGGTGTCCCGGCAGG-3’ and using
K128N/S130T or I156V/K164R as template, respectively.
Generation and titering of soluble SU proteins
293T/17 cells were transfected with SU expression plas-
mids using Lipofectamine LTX reagent (Invitrogen
Corp., Carlsbad, CA) as per the manufacturer’si n s t r u c -
tions. Approximately 48 hours after transfection, SU-con-
taining cell supernatants were collected and filtered to
remove cellular debris. Cell-free supernatants were
mixed with Laemmli Buffer (Bio-Rad Laboratories, Her-
cules, CA) and 2.5% beta-mercaptoethanol, boiled for 5
minutes, and electrophoresed under reducing conditions
in NuPAGE Novex Bis-Tris Mini Gels (Invitrogen Corp.,
Carlsbad, CA). Proteins were transferred to nitrocellulose
and western blot analysis was performed to detect SU
proteins using either the primary antibody C11D8 (Cus-
tom Monoclonals International, West Sacramento, CA)
or mouse anti-HA (Invitrogen, Camarillo, CA) and an
infrared dye-conjugated secondary antibody (Li-Cor Bios-
ciences, Lincoln, NE). SU protein preparations were
thereby quantified using the Odyssey Infrared Imaging
System (Li-Cor). Equivalent mass amounts of each SU
protein were then visualized by western blot analysis
using chemiluminescent detection (Thermo Scientific,
Rockford, IL) to confirm the validity of the quantitation.
Flow cytometric target cell binding assays
Analysis of virus binding to target cells was performed
using cell-free supernatants that contained viral particles
which had been titered by quantifying the 50% tissue
culture infectious dose (TCID50). This was accom-
plished by using limiting dilution assays for infectivity
on FEA cells as described previously [9]. For binding
assays, 4 × 10
6 TCID50 of either 61E/945L or 61E/
945SL were incubated with 5 × 10
5 3201 cells in the
presence of 8 μg/ml hexadimethrine bromide (Sigma-
Aldrich, St. Louis, MO) for one hour at 37°C. Cells were
washed in standard azide buffer (SAB; 1% w/vol FA
Bacto buffer, 0.1% w/vol NaN3, 1% heat-inactivated fetal
bovine serum) and incubated with C11D8 monoclonal
antibody for 1.5 hours at 4°C to detect FeLV SU. Cells
were then washed again in SAB and incubated with a
goat anti-mouse Alexa 488-conjugated secondary anti-
body (Invitrogen Corp., Carlsbad, CA) for 30 minutes at
4°C. Virus-bound cells were analyzed on a Becton Dick-
son FACSCalibur flow cytometer with BD Biosciences
CELLQuest Pro Software. In some cases, binding assays
were performed with pseudotyped particles where 5 ×
10
5 FFU of pseudotyped particles bearing envelope pro-
teins of FeLV-945, FeLV-922, FeLV-1049, FeLV-1306, or
FeLV-1046A [6] were incubated with 5 × 10
4 3201 cells
and processed as described above. Binding assays were
also performed using equivalent mass amounts of solu-
ble SU proteins quantified as described above. Soluble
SU proteins were incubated with 5 × 10
5 target cells for
one hour at 37°C. Cells were washed in phosphate buf-
fered saline containing 2% horse serum and incubated
with either C11D8 antibody or mouse anti-HA antibody
(Invitrogen, Camarillo, CA) for one hour at 4°C. Cells
were then washed as before, incubated with goat anti-
mouse Alexa 488-conjugated secondary antibody for 45
minutes at 4°C, and analyzed by flow cytometry. To
determine the relative dissociation constants (Kd), bind-
ing assays were performed on quadruplicate samples at
increasing concentrations of SU protein from FeLV-A/
61E or from FeLV-945. The relative Kd was then calcu-
lated from the geometric mean fluorescence intensities
obtained in three replicate assays at each concentration
by nonlinear regression analysis using saturation binding
kinetics equations in GraphPad Prism5.0 (GraphPad
Software, Inc., La Jolla, CA) with an assumption of one
site-specific binding. The relative Kd values were used to
calculate receptor occupancy using the following equa-
tion:
Maximal receptor occupancy (Bmax) = [ligand]/([ligand] + Kd).
Computational modelling
Based on the previously reported crystal structure of the
receptor binding domain of FeLV subgroup B [28], the
corresponding residues of FeLV-A/61E and FeLV-945
were submitted for computational modeling by the
SwissModel program [29-31]. The binding cleft domains
of FeLV-A/61E and FeLV-945 SU were modeled using
the SwissModel program [29-31] and the molecular sur-
faces were calculated and drawn using 3D Molecule
Viewer (Vector NTI, Invitrogen Corp., Carlsbad, CA).
Statistical analysis
Statistical analysis of the data from replicate binding
assays was performed using one-way ANOVA and Bon-
ferroni post test.
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